Article Text

Download PDFPDF
Clinical trial of bromhexine in severe chronic bronchitics during winter
  1. S. W. Clarke1,
  2. G. M. Craig,
  3. E. J. B. Makin
  1. Department of Medicine, University of Birmingham, Birmingham, B15 2TH
  2. Queen Elizabeth Hospital, Birmingham, B15 2TH
  3. Boehringer Ingelheim Limited, Isleworth, Middlesex


    In a double-blind, controlled cross-over trial, the effect of the mucolytic drug bromhexine (24 mg or 48 mg daily) was compared with a placebo over a period of 14 weeks in 21 severe chronic bronchitics (mean FEV1·0 0·8 1.). Each of the three treatment regimes was continued for four weeks with intervening single weeks on placebo tablets. As the subjects were outpatients, sodium fluorescein incorporated in the tablets was used as a drug marker. Satisfactory data were obtained in 18 patients. There was no significant improvement in clinical condition or ventilatory capacity nor change in sputum properties throughout the period of study. No side effects or significant change in blood values were detected.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


    • 1 Present address: Brompton Hospital, London S.W.3